ReviewActa pharmacologica Sinica2025

New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024.

Shu Wei Wong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.